Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday. The company’s ...

Roche said it will buy Poseida Therapeutics in a deal worth up to $1.5 billion, as the Swiss pharmaceutical giant seeks to ...

RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.

Swiss pharmaceutical giant Roche announced on Tuesday that it will acquire Poseida Therapeutics, a cell therapy company, for ...

Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics for $1.5 billion ...

Poseida Therapeutics (PSTX – Research Report) received a Hold rating and price target from BTIG analyst Justin Zelin today. The company’s ...

Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

In recent years, biomedical laboratory research has undergone tremendous change, to the extent that computers have frequently ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...

Researchers from the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have published a dataset ...